Whole-Blood DNA Methylation Markers in Early Detection of Breast Cancer: A Systematic Literature Review.


Journal

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608

Informations de publication

Date de publication:
03 2019
Historique:
received: 06 04 2018
revised: 09 07 2018
accepted: 20 11 2018
pubmed: 30 11 2018
medline: 2 5 2020
entrez: 30 11 2018
Statut: ppublish

Résumé

Whole-blood DNA methylation markers have been suggested as potential biomarkers for early detection of breast cancer. We conducted a systematic review of the literature on whole-blood DNA methylation markers for breast cancer detection. PubMed and ISI Web of Knowledge were searched up to May 29, 2018. Overall, 33 studies evaluating 355 markers were included. The diagnostic value of most individual markers was relatively modest, with only six markers showing sensitivity >40% at specificity >75% [only 2 (

Identifiants

pubmed: 30487132
pii: 1055-9965.EPI-18-0378
doi: 10.1158/1055-9965.EPI-18-0378
doi:

Substances chimiques

Biomarkers, Tumor 0
Genetic Markers 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

496-505

Informations de copyright

©2018 American Association for Cancer Research.

Auteurs

Zhong Guan (Z)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.

Haixin Yu (H)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Medical Faculty Heidelberg, University of Heidelberg, Heidelberg, Germany.

Katarina Cuk (K)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Yan Zhang (Y)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany.
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.

Hermann Brenner (H)

Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg, Germany. h.brenner@dkfz.de.
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Division of Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH